News Chasing BMS, Takeda trumpets TYK2 data in psoriasis Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.
News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Dupixent works in hard-to-treat form of atopic dermatitis IL-4 inhibitor shows its worth in atopic hand-foot dermatitis unresponsive to corticosteroids.
News ACELYRIN acquires ValenzaBio, strengthens immunology positio... ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area,
Views & Analysis It’s been a long time coming for long-term topical psoriasis... Psoriasis is a tricky disease to manage, as drawbacks and side effects loom with each and every type of treatment.
News FDA clears Dupixent as first drug for rare skin disorder Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
